These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 35132238)

  • 21. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Yang X; Xu X; Zhang C; Ji T; Wan T; Liu W
    Oral Oncol; 2022 May; 128():105846. PubMed ID: 35358785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
    Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
    J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope.
    Jacky Lam WK; Kang G; Winsome Wong WS
    Ann Oncol; 2023 Dec; 34(12):1080-1081. PubMed ID: 38072511
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
    Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
    Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
    Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment.
    Lele SJ; Adilbay D; Lewis E; Pang J; Asarkar AA; Nathan CO
    Otolaryngol Head Neck Surg; 2024 Aug; 171(2):439-444. PubMed ID: 38591659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma.
    Payne K; Spruce R; Beggs A; Sharma N; Kong A; Martin T; Parmar S; Praveen P; Nankivell P; Mehanna H
    Head Neck; 2018 Jul; 40(7):1598-1604. PubMed ID: 29542214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer.
    Ferrier ST; Tsering T; Sadeghi N; Zeitouni A; Burnier JV
    Cancer Med; 2023 Aug; 12(15):15777-15787. PubMed ID: 37526056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy in head neck cancer: ready for clinical routine diagnostics?
    Tinhofer I; Staudte S; George S
    Curr Opin Oncol; 2023 May; 35(3):151-157. PubMed ID: 36966499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
    Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
    Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer.
    Zhu JW; Wong F; Szymiczek A; Ene GEV; Zhang S; May T; Narod SA; Kotsopoulos J; Akbari MR
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
    Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
    Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of a liquid biopsy for head and neck cancers.
    Schmidt H; Kulasinghe A; Kenny L; Punyadeera C
    Oral Oncol; 2016 Oct; 61():8-11. PubMed ID: 27688098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
    Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
    J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.